Literature DB >> 9431396

Rifampin-monoresistant tuberculosis in New York City, 1993-1994.

S S Munsiff1, S Joseph, A Ebrahimzadeh, T R Frieden.   

Abstract

All New York City patients whose cultures yielded Mycobacterium tuberculosis with isolated resistance to rifampin in 1993 and 1994 were included in this study. Of the 96 patients, 48 (50%) had primary resistance, 32 (33%) had acquired resistance, and 16 (17%) had unclassified resistance; 66% had histories of illicit drug use, and 79% were infected with human immunodeficiency virus (HIV). The median time to emergence of resistance was 40 weeks among the 32 patients with acquired resistance. Each of the HIV-infected patients with acquired resistance (cases, n = 29) was matched to two HIV-infected patients who had disease due to fully susceptible M. tuberculosis (controls, n = 58). In multivariate analysis, factors associated with the emergence of rifampin resistance were as follows: a sputum smear positive for acid-fast bacilli, advanced immunosuppression, and nonadherence to therapy.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9431396     DOI: 10.1086/516146

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  16 in total

Review 1.  Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials.

Authors:  W J Burman; K Gallicano; C Peloquin
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

2.  Long-term Mortality of Patients With Tuberculous Meningitis in New York City: A Cohort Study.

Authors:  Christopher Vinnard; Liza King; Sonal Munsiff; Aldo Crossa; Kentaro Iwata; Jotam Pasipanodya; Douglas Proops; Shama Ahuja
Journal:  Clin Infect Dis       Date:  2017-02-15       Impact factor: 9.079

3.  Immunodeficiency and Intermittent Dosing Promote Acquired Rifamycin Monoresistance in Murine Tuberculosis.

Authors:  Sang-Won Park; Rokeya Tasneen; Paul J Converse; Eric L Nuermberger
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

4.  Rise in rifampicin-monoresistant tuberculosis in Western Cape, South Africa.

Authors:  F K Mukinda; D Theron; G D van der Spuy; K R Jacobson; M Roscher; E M Streicher; A Musekiwa; G J Coetzee; T C Victor; B J Marais; J B Nachega; R M Warren; H S Schaaf
Journal:  Int J Tuberc Lung Dis       Date:  2012-02       Impact factor: 2.373

5.  Rifampicin-monoresistant Mycobacterium tuberculosis disease among children in Cape Town, South Africa.

Authors:  A Dramowski; M M Morsheimer; A M Jordaan; T C Victor; P R Donald; H S Schaaf
Journal:  Int J Tuberc Lung Dis       Date:  2012-01       Impact factor: 2.373

6.  Antituberculosis drug resistance acquired during treatment: an analysis of cases reported in California, 1994-2006.

Authors:  Travis C Porco; Peter Oh; Jennifer M Flood
Journal:  Clin Infect Dis       Date:  2012-12-07       Impact factor: 9.079

Review 7.  Tuberculosis and HIV disease: two decades of a dual epidemic.

Authors:  Muktar H Aliyu; Hamisu M Salihu
Journal:  Wien Klin Wochenschr       Date:  2003-10-31       Impact factor: 1.704

Review 8.  Extensively drug-resistant tuberculosis: a new face to an old pathogen.

Authors:  Sheela Shenoi; Gerald Friedland
Journal:  Annu Rev Med       Date:  2009       Impact factor: 13.739

9.  Xpert(®) MTB/RIF detection of rifampin resistance and time to treatment initiation in Harare, Zimbabwe.

Authors:  J Z Metcalfe; S Makumbirofa; B Makamure; C Sandy; W Bara; P Mason; P C Hopewell
Journal:  Int J Tuberc Lung Dis       Date:  2016-07       Impact factor: 2.373

10.  Rifampin monoresistant tuberculosis and HIV comorbidity in California, 1993-2008: a retrospective cohort study.

Authors:  Lisa M Prach; Lisa Pascopella; Pennan M Barry; Jennifer Flood; Travis C Porco; Philip C Hopewell; John Z Metcalfe
Journal:  AIDS       Date:  2013-10-23       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.